Tesamorelin 20 - Reduce Excess Abdominal Fat

Tesamorelin is a  synthetic growth hormone-releasing hormone (GHRH) analogue that has  gained FDA approval for a specific medical use. Here are the key points  about Tesamorelin: Composition: Tesamorelin is a  synthetic peptide that mimics the action of growth hormone-releasing  hormone (GHRH), a naturally occurring hormone in the body. FDA Approval: Unlike many  other peptides we’ve discussed, Tesamorelin is FDA-approved for a  specific medical condition: to reduce excess abdominal fat in  HIV-infected patients with lipodystrophy. Brand Name: It’s marketed under the brand name Egrifta. Mechanism of Action:  Tesamorelin stimulates the pituitary gland to produce and release more  growth hormone naturally, rather than directly supplying growth hormone  to the body. Primary Use: Its main approved  use is to reduce visceral adipose tissue (VAT) in HIV-infected patients  with lipodystrophy, a condition where body fat is abnormally  distributed. Potential Effects:Reduction of visceral fat Potential improvement in lipid profiles Possible cognitive benefits (under investigation) Research Status: While  approved for use in HIV-related lipodystrophy, research is ongoing for  its potential in other areas, including cognitive function and  non-alcoholic fatty liver disease (NAFLD). Side Effects: Common side  effects can include injection site reactions, joint pain, and mild  swelling in extremities. As it increases growth hormone levels, it may  also increase the risk of certain cancers. Regulatory Status: Unlike many  peptides sold as research chemicals, Tesamorelin is a prescription  medication in countries where it’s approved. Off-label Interest: Due to its  effects on body composition, there’s interest in its potential use for  anti-aging and performance enhancement, though these are not approved  uses. Ongoing Research: Studies are  exploring its potential in treating cognitive decline, particularly in  HIV patients, and its effects on metabolism and body composition in  non-HIV populations. It’s important to note that  while Tesamorelin is FDA-approved for a specific condition, this doesn’t  mean it’s safe or effective for other uses. Its use should be under  strict medical supervision and only for its approved indications. The  long-term effects of Tesamorelin use, particularly in populations other  than HIV patients with lipodystrophy, are not fully understood. Properties of Tesamorelin Chemical Formula: C221H366N72O67S Molecular Mass: 5135.9 Synonyms: TH9507 Molar Mass: 5135.9 CAS Number: 218949-48-5 PubChem: 11597566 Vial Size: 3ml Vial Contents: Lyophilized Powder (>99% purity)